Peter Turnbaugh

Peter Turnbaugh is a Professor at the University of California San Francisco School of Medicine, where he leads an interdisciplinary research group focused on understanding host-associated microbes and their implications for medicine. His work spans multiple scales of biological organization, from molecular mechanisms to ecological interactions within the gut microbiome, with particular emphasis on how these complex microbial communities impact human health and disease.

Dr. Turnbaugh earned his B.A. in Biochemistry, Biophysics, and Molecular Biology from Whitman College in 2003, followed by a Ph.D. in Molecular Genetics and Genomics from Washington University in Saint Louis in 2009. He completed postdoctoral training in Systems Biology at Harvard University in 2014. His academic journey reflects a strong foundation in both molecular biology and systems-level approaches to biological complexity.

His research program centers on three major interconnected areas: pharmacology, nutrition, and phage biology as they relate to the gut microbiome. Turnbaugh's lab employs a question-driven approach that ranges from molecular techniques (biochemistry, bacterial genetics, structural biology) to organismal studies (gnotobiotic mice, conventional animal models, clinical trials) to ecological analyses (synthetic microbial communities, metagenomic sequencing). A key focus is understanding how the gut microbiome influences drug metabolism and treatment outcomes, with implications for personalized medicine.

Analysis of Dr. Turnbaugh's recent publications reveals a sophisticated integration of microbiome science with pharmacology and immunology. His work systematically examines how gut bacteria metabolize drugs, influence treatment efficacy and toxicity, and interact with host physiology across multiple disease contexts. Key emerging themes include microbial contributions to chemotherapy outcomes, diet-microbiome-drug interactions, and the development of novel approaches to manipulate the gut microbiome for therapeutic benefit, reflecting a maturing field moving toward clinical applications.

Dr. Turnbaugh has received numerous prestigious awards recognizing his contributions to microbiome research:

• Searle Scholar (2017)
• CZ Biohub Investigator, Microbiome Initiative (2018)
• ASM Young Investigator Award (2018)
• Damon Runyon-Rachleff Innovation Award (2016)
• Burroughs Wellcome Fund Investigators in the Pathogenesis of Disease Award
• Multiple UCSF awards for breakthrough biomedical research

His research is robustly supported by multiple NIH grants as Principal Investigator, including R01HL122593 (Predicting and preventing drug metabolism by the human gut microbiome), R01DK114034 (Host-microbiome interactions shape the metabolic effects of ketogenic diets), R01AT011117 (Establishing the feasibility of editing the human gut microbiome), and R21CA227232 (Harnessing the human gut microbiome to predict chemotherapy outcomes). As a Co-Principal Investigator, he also leads R01AR074500 on rheumatoid arthritis therapy. His lab actively embraces high-risk, high-reward projects and thrives on interdisciplinary collaboration, positioning his work at the forefront of microbiome science translation to clinical practice.

Turnbaugh leads an innovative team committed to reducing complex microbial ecologies to molecular mechanisms and applying these insights to improve medical practice. His laboratory combines cutting-edge genomic, biochemical, and physiological approaches to address fundamental questions about host-microbe interactions, with particular emphasis on developing mechanistic understanding that can inform therapeutic strategies for a range of conditions influenced by the microbiome.